were confirmed to be bound to PA and decreased the activity of the
viral RNA polymerase89. More recently, Kessler, et al., discovered
benzofurazan-based novel inhibitors targeting PA–PB1 binding interfaces
using an ELISA-based high-throughput screening method.
However, this serie of compounds has unfavorable toxicity profiles
for in vivo use. Overall, the PA–PB1 binding interface has emerged to
be a potential fruitful target for a new generation of anti-influenza A
drug development.